Kornimate/medical-research-clean huggingface dataset:
rfa+highly-purified ctl vs. rfa alone for recurrent hcc

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is the fifth most common and the third leading cause of cancer-related death worldwide. recurrence of tumor within the liver remnant is common, with a reported 5-year recurrence rate of 70%. repeat hepatectomy is an effective treatment for intrahepatic hcc but with a small proportion of resection rate because of the poor functional liver reserve and postoperative complications. radiofrequency ablation(rfa) is becoming the main effective treatment for small hcc (≤5.0cm). the efficacy of rfa for recurrent hcc has been reported to be comparable to those achieved by surgery with minimal, but higher local recurrence rate after rfa. it has been reported that immunotherapy in patients who underwent curative treatment for hcc, adjuvant immunotherapy with activated cik cells increased recurrence-free and overall survival. but there is little evidence for adjuvant immunotherapy of recurrence hcc. cytotoxic t lymphocytes(ctl), a kind of effective t cells that specific recognizing and killing antigen targeted cells through cloning amplification after receiving antigen information from antigen presented cell and playing key role to clear cancerous cells. so our hypothesis is that rfa combined with immunotherapy (highly-purified ctl) is superior to rfa for recurrent hcc. the aim of this prospective study is to compare the outcome of rfa combined with immunotherapy (highly-purified ctl) with rfa for small recurrent hcc after partial hepatectomy.


Eligibility criteria:
inclusion criteria: 1. age 18-75 years; 2. recurrence of hcc 12 months after initial hepatectomy; 3. no other treatment received except for the initial hepatectomy; 4. single tumor≤5.0cm in diameter; or 2-3 lesions each≤3.0cm; 5. lesions visible on ultrasound and with an acceptable and safe path between the lesion and the skin as shown on ultrasound; 6. no severe coagulation disorders (prothrombin activity\<40% or a platelet count\<40,000/mm3); 7. eastern co-operative oncology group performance(ecog) status 0-1. exclusion criteria: 1. pregnant women, breastfeeding women or plan pregnancy for the future 2 years; 2. the presence of vascular invasion or extrahepatic spread onimaging; 3. usage of strong immunosuppressive agents such as corticosteroids, cyclosporine a within six months or longer; 4. hiv antibody or hcv antibody positive; 5. immunodeficiency diseases or autoimmune diseases (such as rheumatoid arthritis, buerger's disease, multiple sclerosis and type 1 diabetes); 6. suffering with cancers (except skin cancer, prostate cancer or cervical carcinoma in situ) at the enrolling time or 5 years before; 7. suffering with other organ failure; 8. suffering with severe mental illness; 9. drug addiction (including alcohol) for 1 year before the enrolling time; 10. participate in other clinical trials within three months prior to 3 months before the enrolling time; 11. other researchers believe that the patient is not fit for inclusion.
rct comparing the dexa results of the ha-omnifit versus the symax uncemented hip stem

Conditions: Patients With Osteoarthritis of the Hip Joint Elligable for a Uncemented Hipprosthesis

Summary: thr purpose of this study is to compare the clinical and radiological results, as well as the femur bone density measurements of two uncemented total hip prostheses during 5 years of follow up.

it is of great importance for the function of uncemented total hip arthroplasty that the anchorage of the prosthesis in the bone of the femur is sufficient. this is of great importance in the prevention of stress shielding of the bone and to insure tranfer of forces from the prosthesis to the femur. the symax hip stem is developed to optimize stress tranfer to bone and insure mechanical stability. in this study the symax hip stem is compared to the ha_omnifit hip stem (a frequently used and long term evaluated uncemented hip prosthesis) during the fist two years of follow up dexa mesurments of bone mineral density are performed. also patient satisfaction, patient fuction score and radiological evaluation measurements are done during 5 years of follow up. our primary objective is: comparison of the short term bone remodelling surrounding the symax hip stem to the short term remodeling surrounding the stryker omnifit ha hip stem measured by bone densitometry, clinical and radiographic evaluation.

Eligibility criteria:
inclusion criteria:male or non pregnant female patients \>18 years * patient with degenerative or traumatic changes to hip requiring hip replacement * patient with bmi\<35 * patient signed informed consent exclusion criteria: * chronic anti-inflammatory medication use\> 3 months * revision surgery to the affected femur * cancer therapy including immunosuppression, chemotherapy and radiation * pathological fractures, delayed ossification or non-union is likely to occur

Keywords: uncemented hip bone remodeling dexa clinical evaluation
exparel injection effect on postoperative opioid usage

Conditions: Thyroid; Parathyroid Adenoma

Summary: the question proposed by this study, is one of patient outcomes. does intraoperative injection of exparel decrease postoperative use of opioid pain medications in patients undergoing thyroid and parathyroid surgery? the trial seeks to assess the effect that exparel has on postoperative pain control.

patients will be identified in clinic as good candidates for surgical intervention based on current standard of care. once participants are consented, they will be randomly placed into one of three categories. the first category being patients undergoing surgery with local injection of lidocaine and epinephrine as is current practice. the second category of patients will undergo surgery with local injection of bupivacaine hcl and epinephrine preincision. the third group will undergo surgery with local injection of lidocaine and epinephrine preincision and exparel postincision. as stated above, all patients will undergo surgery as planned, which will be standard of care, with the exception of the local anesthetic and timing of the injection. postoperatively, patient's pain scores and opioid usage will be evaluated. patients will be monitored by either using the patient's electronic medical record or by a pain journal that will be provided to the patients. the patients will record their pain using a scale of 1-10 with the faces scale, as well as medication usage. patients will return to their first postoperative appointment to further discuss their pain levels as well as medication usage. an anova test will be used to determine if there is a significant difference in the amount of opioids taken postoperatively, in oral morphine equivalents, between these three groups. opioid usage will then be compared between participants in different categories of local anesthetic to determine if there is an effect of postoperative opioid usage between different anesthetics.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 years patients requiring parathyroid/thyroid surgery based on the standard of care english as primary language exclusion criteria: * patients under the age of 18 years patients with previous history of opioid abuse patients with a true allergy to any local anesthetic patients with a true allergy to any opioid
study of ablation versus antiarrhythmic drugs in persistent atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to compare the effectivity and safety of atrial fibrillation ablation, in comparison to antiarrhythmic drug therapy in patients with refractory, persistent atrial fibrillation.


Eligibility criteria:
inclusion criteria: * patients with persistent atrial fibrillation (more than 7 days, or less than 7 days needing pharmacologic or electric cardioversion) exclusion criteria: * hypo or hyperthyroidism * persistent atrial fibrillation lasting more than 1 year or non-defined duration * hypertrophic myocardiopathy * implantable defibrillation or pacemaker implanted * moderate or severe mitral valve disease or mitral prosthetic valve * ejection fraction less than 30% * left atrial anteroposterior diameter more than 50 mm. * previous atrial fibrillation ablation * contraindication to anticoagulation * left atrium thrombus * current infective disease or sepsis * pregnant women * current unstable angor * acute myocardial infarction in last 3 months * atrial fibrillation secondary to ionic disturbance, thyroids disease or secondary to any other reversible or non cardiovascular disease * reduced expectancy of life (less than 12 months) * patient participating in another clinical study that investigates a drug or device * psychologically unstable patient or denies to give informed consent * any cause that contraindicate ablation procedure or antiarrhythmic drug

Keywords: catheter ablation, radiofrequency atrial fibrillation antiarrhythmic drugs
a pk study gl2702 glars-nf1 and omix ocas® in healthy male volunteers

Conditions: Healthy

Summary: study to investigate the pharmacokinetics of gl2702 glars-nf1 and omix ocas® in healthy male volunteers

gl2702 glars-nf1 tablet is controlled released formulation which is invented by gl pharm tech corp.

Eligibility criteria:
inclusion criteria: * 20\~45 years old, healthy adult male subject * body weight ≥ 50kg and ideal body weight ≤ ±20% exclusion criteria: * alt or ast \> 1.25 times (upper normal range) * total bilirubin \> 1.5 times (upper normal range) * cpk \> 2 times (upper normal range) * bun or creatinine \> normal range * systolic bp \> 160mmhg or \ 100mmhg or \< 50mmhg

Keywords: tamsulosin,controlled release formulation
study on musculoskeletal disorders in spanish pianist

Conditions: Musculoskeletal Diseases

Summary: background: musculoskeletal disorders related to instrumental practice (tmrpi) affect many pianists. objectives: to know the prevalence of tmrpi in the population of spanish pianists and its relationship with gender, age, physical activity, number of years playing the piano and the number of hours per week. design: transversal study based on a survey that included 30 volunteers of both genders, aged between 17 and 65, who played the piano for at least 2 years. method. due to the absence of specific questionnaires for pianist populations on mmrpi, a questionnaire was conducted combining a validated questionnaire on mmr, the nordic musculoskeletal questionnaire (nmq) with an "ad hoc" questionnaire created specifically for this study


Eligibility criteria:
inclusion criteria: * over 16 years old * at least 2 years playing piano exclusion criteria: * traumatism

Keywords: assessments pain physical therapy specialty musics
motor learning approaches from working on a vertical surface in hemiplegic children's upper limb motor skills

Conditions: Hemiplegia; Spastic

Summary: working on a vertical surface is one of the best activities children can do to make themselves more successful in many areas as an infant which builds all those foundational skills required for the all-important task of handwriting.

motor-learning approaches such as - constraint-induced movement therapy (cimt) offer an array of sensorimotor experiences in a playful yet repetitive and intense fashion. a stable shoulder girdle is the co-contraction of muscles around the scapula and shoulder joint. depending on the activity, vertical surfaces will have kids moving their arms frequently; reaching up, down, out and around. this supports extension of the arm and an opportunity to strengthen those muscles. vertical surfaces facilitate wrist extension. when the wrist is extended, the ring and pinky finger tend to naturally find their way into the palm creating a more optimal grasp pattern. a child is going to be able to execute more precise and legible work when using a functional tripod or quadrupod grasp.

Eligibility criteria:
inclusion criteria: 1. children diagnosed with spastic hemiplegic cerebral palsy 2. age 5 to 9 years 3. manual ability classification system (macs)19 scores i, ii. 4. children who can understand and cooperate with researcher's instructions 5. children with no visual or hearing impairment exclusion criteria: 1. children with any surgical interference in the upper limb. 2. intellectual disability such that simple tasks could not be understood or executed. 3. inability to combine the study protocol with the regular school program

Keywords: motor learning vertical surface hemiplegia cerebral palsy
insertable cardiac monitors in hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy

Summary: hypertrophic cardiomyopathy (hcm) is associated with sudden cardiac death and an increased risk of atrial fibrillation and subsequent embolic event. an insertable cardiac monitor will provide data on cardiac rhythm over a period of 18 months. this will provide an extended monitoring far longer than 24-48 hours of holter monitoring as is currently usual care. therefore, detection of arrhythmias could be used in risk stratification and decision-making with regard to offer an implantable defibrillator and anticoagulants.

detection of non-sustained ventricular tachycardia (nsvt) and atrial fibrillation (af) using an insertable cardiac device monitor (sjm confirm xt) which is connected to the patients smart phone and monitored for 18 months.

Eligibility criteria:
inclusion criteria: * hypertrophic cardiomyopathy exclusion criteria: * aortic stenosis (moderate, severe) * hypertrophic cardiomyopathy associated with metabolic disease (e.g. fabry) and syndromes (e.g. noonan) * systolic heart failure * cardiac device (previous pacemaker, implantable defibrillator ) * history of myocardial infarction * percutaneous coronary intervention and/or coronary artery by-pass grafting * pulmonary vein isolation, maze surgery, ventricular tachycardia ablation, ectopic atrial tachycardia ablation * renal clearance below 40 * malignancy or other comorbidity with less than five years life expectancy * pregnancy of planned within 18 months * drug addiction, severe mental disease * not able to participate in 18 months follow-up * 5 years risk more than 6% according hcm risk calculator of european society of cardiology guidelines.

Keywords: insertable cardiac monitor atrial fibrillation non-sustained ventricular tachycardia
screening wizard, component 1 of ichart (integrated care to help at-risk teens)-feasibility/pilot phase

Conditions: Depression; Suicidal Ideation

Summary: screening wizard (sw). primary care providers (pcps) are often uncertain about how to best refer adolescents who screen positive for depression or suicidality. screen-positive youth who are either not in treatment, or express dissatisfaction with current treatment will be consented by an on-site research assistant (ra). those parents and patients receiving sw will answer additional questions: adaptive screens developed in a previous nimh study (mh100155) for suicidal risk, anxiety, and mania; perceived barriers; and preferences about treatment. sw generates recommendations for pcps reflecting patient clinical needs and preferences.

screening wizard will be delivered by primary care providers (pcps) at well child visits, beginning with screening occurring within the waiting room which will yield decision support guidance delivered and followed by the pcp at that same visit. this study utilized an open trial design. a stepped wedge design was originally proposed and efforts were made to adhere to this study design, however after a year of low recruitment and resultant recruitment sites pulling out the of the study, the overall study design was changed to an open trial. additional recruitment sites were onboarded to the study and provided with the intervention arm in order to obtain feasibility data on the intervention components of the study. for reference a stepped wedge design involves the sequential random rollout of an intervention over two time periods. following a baseline period in which no clusters (=practices) are exposed to the intervention, the crossover is typically in one direction, from control to intervention and continues until both of the clusters have crossed-over to receive the intervention, with observations taken from each cluster and at each time period. hypothesis: the use of screening wizard will increase the rate of personalized referrals experts in specialty mental health would provide, compared to treatment as usual (tau).

Eligibility criteria:
inclusion criteria: * youth aged 12-26 yo * biological or adoptive parent is willing to provide informed consent for teen to participate * youth speaks and understands english exclusion criteria: * non english speaking * no parent willing to provide informed consent * is currently experiencing acute mania or psychosis, evidence of an intellectual or developmental disorder (idd), life threatening medical condition that requires immediate treatment, or other cognitive or medical condition preventing youth from understanding study and/or participating.
usefulness of an assistive technology training program for adolscents with dyslexia

Conditions: Dyslexia; Adolescent

Summary: specific written language disorders (swld) are severe and lasting impairments in the development of written language that affect approximately 10% of the school-age population.concerned patients don't have any intellectual disability. speech therapy help them to improve their language skills but also to compensate for their difficulties. school environment is one of the places where these disorders can constitute a real handicap. given the prevalence of disorders, governments but also supra-governmental authorities have promoted educational integration of the concerned patients around the world. in france, different systems exist to help these patients with swld to follow an education that allows them to update their capacities as much as possible. school facilities are proposed such as attribution of assistive technology (at). nevertheless, these facilities have some limitations. concerning at, several studies have shown the benefits for patients with dyslexia such as a better use of them. however, there were some limitations in their use and their usefulness. the lack of use training is one of the barriers cited by patients and caregivers (parents and teachers). assistive technology training exists for patients with dyslexia but very few studies have measured their influence on their performance in written language. moreover, these studies did not take into account the previous level of computer practice nor the natural appropriation of the at (ie: anyone can appropriate themselves). it is therefore difficult to affirm the specificity of the training's influence. this study aims to assess the usefulness of at training on the written language performance of adolescents with dyslexia. this work will study teenager's autonomy and how they use these tools.


Eligibility criteria:
inclusion criteria: * adolescents with dyslexia * normal schooling (not in a specialized establishment) * with attribution of assistive technology less than 3 months or planned soon or low usage exclusion criteria: * oral disabilities hindering intelligibility * physical disabilities (hands) hindering use of at * auditive and visual disabilities

Keywords: dyslexic adolescent dyslexia education assistive technology
a placebo-controlled study to investigate the onset of action of paroxetine in premenstrual dysphoria

Conditions: Premenstrual Dysphoric Disorder; Premenstrual Syndrome

Summary: the objective of this study is to explore the onset of action when serotonin reuptake inhibitors are used to treat premenstrual dysphoric disorder

whereas serotonin reuptake inhibitors (sris) usually require weeks of treatment to effectively counteract depressed mood or anxiety, several studies suggest that they may reduce the symptoms irritability and anger more rapidly. in line with this, sris have been shown to reduce certain symptoms, including irritability, in women with premenstrual dysphoric disorder (pmdd) when the drug only is administered from ovulation to menstruation only, which indicates an onset of action of 10 days or less. how fast this effect appears in terms of hours or days is, however, not known. the objective of this study was to explore this issue.

Eligibility criteria:
inclusion criteria: * the patient should have participated in an ongoing placebo-controlled trial regarding the effect of paroxetine in pmd; to be included in that trial, she must have fulfilled the diagnostic criteria a-c of pmdd in dsm-iv and certain other inclusion and exclusion criteria which are listed in appendix 1. * the patient should a) have been given paroxetine during the previous trial, b) have reported that she has been "much improved" or "very much improved" by this treatment, c) have displayed a marked reduction in vas-rated irritability during treatment, and d) have reported that she has found the side-effects tolerable. * the patient should display at least a 50% increase in vas-rated irritability during the luteal phase (mean of last five days prior to menses) as compared the follicular phase (days 6-10) during one cycle of pretreatment symptom rating (without medication). * the patient should have given written informed consent to participate in the study. exclusion criteria: * any concomitant psychiatric disorder for which sris are known to be effective. * any other concomitant psychiatric disorder that, in the investigator's opinion, would render the patient unsuitable for the study. * any somatic disorder that, in the investigator's opinion, would render the patient unsuitable for the study. * any ongoing medication which, in the opinion of the investigator, would render the patient unsuitable for the study. examples of medications that preclude participation in the study are: 1) any psychotropic drug, with the exception of the occasional use of hypnotics, 2) any hormonal preparation, with the exception of thyroid hormone, 3) anti-coagulants, and 4) 5ht1d agonists. occasional use of analgesic compounds does not preclude participation. * patient characteristics which, in the opinion of the investigator, are likely to reduce compliance with the protocol.

Keywords: paroxetine onset of action serotonin reuptake inhibitors
ebus score validation for malignancy

Conditions: Lung Neoplasms; Lung Diseases

Summary: surgical removal of a tumour in the lung offers the best chance for survival in early stage lung cancers. one main criteria of surgical eligibility is the absence of cancer spread to the lymph nodes; rendering the staging process extremely important. the evaluation of these lymph nodes is thought to be best completed using endobronchial ultrasound (ebus), a procedure in which several lymph nodes are sampled and send to pathology to determine whether or not it is malignant. more recently, studies have observed that there are clear differences in the characteristics of cancerous and benign (non-cancerous) lymph nodes, and so there has been great interest in creating a list of criteria that can determine whether a node is malignant. this study aims to prospectively validate a previously proposed score based on observed characteristics of lymph nodes during an ebus procedure relating to pathology-confirmed results. to test this, the results of the lymph node samples and the observed score will be compared for agreement. if the investigators find that the scoring system can accurately predict which lymph nodes are cancerous, it would provide the evidence to establish the score as a standard procedure during cancer staging.


Eligibility criteria:
inclusion criteria: * must be diagnosed with confirmed or suspected lung cancer and be undergoing ebus diagnosis/staging exclusion criteria: * n/a

Keywords: ebus prediction malignancy lymph nodes lung cancer diagnostic techniques, respiratory system